Full-Time

Senior Clinical Data Associate-Risk-Based Quality Monitoring

Rbqm

Posted on 10/1/2024

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Senior

Remote in USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform
Requirements
  • S./B.A. in a science or technical discipline degree with 6 years Clinical data management experiences, or M.S./Ph.D./M.D. degree with 4 years Clinical data management experiences
  • Familiar with clinical trial life cycle, proficient in clinical data collection, cleaning and locking for Phase I- IV clinical trials in a pharmaceutical industry/CRO
  • Prior experience working with RBQM methodologies, TSDV configuration and management, establishment of KRIs and QTLs, and central monitoring modalities is required
  • Working knowledge of ICH/Good Clinical Practices (GCP), Good Clinical Data Management Practices (GCDMP), and related regulatory requirements. CCDM is preferred but not required
  • Working knowledge of CDISC CDASH/SDTM standards, medical terminology, and medical coding dictionaries: MEDDRA and WHODRUG
  • Working knowledge of different EDC and TSDV platforms and data collection systems (e.g. IRT, ePRO, etc.)
  • Prior experience supporting a BLA or NDA filing preferred but not required
  • Experience managing CRO vendors
  • Ability to manage multiple initiatives and shifting priorities within a small company environment
  • Excellent interpersonal skills with the ability to work independently and collaboratively in a dynamic team environment
Responsibilities
  • Serve as primary data management representative supporting RBQM activities on cross-function project teams and ensure effective communication exchange
  • Manage, collaborate, and act as the primary point of contact with CROs to ensure that study deliverables and timelines are met for outsourced studies
  • Monitor Data Management RBQM processes and CRO performance
  • Lead RBQM activities with external vendors ensuring timely reporting of Key Risk Indicators and Quality Tolerance Levels to allow for adaptive risk-based monitoring
  • Assist study data management personnel with the configuration and management of Targeted Source Document Verification (TSDV) in EDC both at study start-up as well as throughout the conduct of studies as RBQM metrics are measured
  • Conduct trainings for appropriate users of data management systems (e.g. EDC, RBQM reports, TSDV)
  • Generate and/or review/approve study documents (e.g. Data Management Plans, RBQM reports and visualizations, data transfer specifications, SAE and/or external data reconciliation plans, coding conventions, study protocols)
  • Ensure the quality of clinical data meets standards determined by RBQM KRIs and QTLs and is fit for regulatory submissions. Generate and/or implement the Data Review Plan (DRP) and/or Central Monitoring Plan defining and documenting the data quality review strategy for each clinical trial in collaboration with cross-functional team, enabling the quality review of patient data supporting regulatory filings, publications and other high-profile business activities
  • Work with CROs to generate and/or distributes data management metrics, RBQM deliverables, data listings and status reports

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a range of drugs in clinical trials, including omecamtiv mecarbil and reldesemtiv, aimed at treating conditions like heart failure, ALS, and HCM. What sets Cytokinetics apart from competitors is its dedicated focus on muscle-related diseases and its extensive pipeline of potential treatments. The goal of Cytokinetics is to bring effective therapies to market that address the unmet medical needs of patients suffering from debilitating muscle conditions.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

14%
Simplify Jobs

Simplify's Take

What believers are saying

  • Cytokinetics secured $575M funding from Royalty Pharma for R&D and commercial launch.
  • Positive Phase III results for aficamten in treating obstructive hypertrophic cardiomyopathy.
  • Increased investment interest, with $1.73M from Intech and $1.88M from Bridger Management.

What critics are saying

  • Competition from Bristol-Myers Squibb's Camzyos in hypertrophic cardiomyopathy market.
  • Reliance on successful clinical trial outcomes for financial stability.
  • Need for substantial capital, indicated by recent public offering and external funding.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
  • The company targets niche markets like hypertrophic cardiomyopathy and amyotrophic lateral sclerosis.
  • Cytokinetics has a robust pipeline including omecamtiv mecarbil and aficamten.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE